The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -20.98 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 27.95 — flag raised, worth a closer lookWatch
- Earnings quality 48/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Onconetix, Inc. reports it. History and quarterly detail are in the app.
- Other Revenues$588K
- Product Sales$226K
- Development Service$2K
- License$1
Leadership changes
From Onconetix, Inc.'s own filings, the day they're filed.
- Sammy Dorf · Chairman · appointmenteff. 2026-04-23
- Andrew Oakley · Chairman · departureeff. 2026-04-20
- Thomas Meier · Chairman · departureeff. 2026-04-20
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-05-19
- 8-K · Company announcement2026-05-14
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Onconetix, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Onconetix, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.